Xbrane Sets Date For Latest Run At Ranibizumab In US
Awaits Manufacturing Sites Inspection Ahead Of October BsUFA Date
After a series of setbacks for its Lucentis (ranibizumab) biosimilar filing in the US, Xbrane Biopharma now has a fresh action date from the FDA – although any approval will be contingent on a successful agency reinspection of its manufacturing sites.
